Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room: UCB Announces Launch of Nile AI, Inc.


[13/01/2021 | 07:01]

** UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to T=
ransform the Course of Epilepsy

=C2=B7 Nile is developing a digital epilepsy care management platform and b=
ringing together data to make the epilepsy journey predictable.
=C2=B7 UCB invested =E2=82=AC25 million ($29.3 million) and as majority sha=
reholder, will sit on the Board of Directors of Nile with future opportunit=
ies to acquire insights and data from Nile=E2=80=99s platform.

Brussels (Belgium) and Atlanta, Ga. 13 January 2021 =E2=80=93 7:00a (CET) -=
UCB today announced the launch of Nile AI, Inc., a new independent company=
created to improve care for people living with epilepsy, their caregivers,=
and healthcare providers (HCPs). Nile was founded with a clear mission in =
mind: to make the journey of every epilepsy patient predictable. To that en=
d, Nile is developing an epilepsy care management platform that serves as a=
digital extension of the healthcare provider (HCP) and provides patients w=
ith peace of mind between consultations, with the ultimate goal of shorteni=
ng the path to optimal treatment.=C2=A0

UCB=E2=80=99s =E2=82=AC25 million ($29.3 million) investment is part of UCB=
=E2=80=99s overall commitment to improving the lives of people living with =
severe diseases, including epilepsy, as digital technologies continue to ch=
ange and impact the way healthcare is delivered. As a majority shareholder,=
UCB will will sit on the Board of Directors of Nile with future opportunit=
ies to acquire insights and data from Nile=E2=80=99s platform.

=E2=80=9CUCB has a deep understanding of epilepsy and the challenges that p=
eople living with the disease face every day, including how patients commun=
icate with their healthcare providers. We think Nile=E2=80=99s platform can=
provide valuable insights and foster a better care management experience f=
or people living with epilepsy,=E2=80=9D said Charl Van Zyl, Executive Vice=
President, Head of Neurology Solutions and International Markets, UCB. =E2=
=80=9CThe launch of Nile is a further illustration of UCB=E2=80=99s commitm=
ent and leadership in epilepsy, and how digital platforms can help provide =
transformational outcomes and experiences for patients.=E2=80=9D=C2=A0

Nile=E2=80=99s digital platform consists of a patient app and HCP portal. T=
he patient app is an intuitive, smart tool for patients to feel connected w=
ith their care team, learn about their journey, and understand their progre=
ss. The HCP portal shows the status of their patients at a glance, virtuall=
y informs and supports their patients in between appointments, and allows d=
ata-driven decisions on treatment and care. Nile is currently testing the p=
latform in usability studies with two U.S. healthcare systems, Massachusett=
s General Hospital and Michigan State University Healthcare. The platform i=
s expected to be commercially available in 2021.=C2=A0

=E2=80=9CWe know that patients suffering from epilepsy struggle with the un=
predictable nature of their lives,=E2=80=9D said Dr. Leo Petrossian, Chief =
Executive Officer of Nile AI, Inc. =E2=80=9CEvery single day they awake unc=
ertain of what they can expect. At Nile, we believe that all of the data to=
predict the path of an epilepsy patient exists, though it is fragmented an=
d disconnected. We are building a comprehensive care management system for =
addressing this uncertainty in the lives of people suffering from epilepsy.=

Nile is a collaboration-driven organization and is welcoming partners in th=
is mission. To create lasting impact in the lives of patients, Nile aims to=
identify the essential work in the epilepsy ecosystem, align efforts acros=
s various fields, and amplify them under one roof. The company is headquart=
ered in Los Angeles, California. For more information, visit www.Nile.ai.

UCB supports new digital platforms in its mission to transform the way care=
is delivered and accelerate better outcomes for people living with severe =
diseases as part of its digital business transformation now and in the futu=

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 7 500 people in=
approximately 40 countries, UCB generated revenue of =E2=82=AC 4.9 billion=
in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Tw=
itter: @UCB_news

About UCB in Epilepsy=C2=A0
UCB has a rich heritage in epilepsy with over 20 years of experience in the=
research and development of anti-epileptic drugs. As a company with a long=
-term commitment to epilepsy research, our goal is to address unmet medical=
needs. Our scientists are proud to contribute to advances in the understan=
ding of epilepsy and its treatment. We partner and create super-networks wi=
th world-leading scientists and clinicians in academic institutions, pharma=
ceutical companies, and other organizations who share our goals. At UCB, we=
are inspired by patients, and driven by science in our commitment to suppo=
rt patients with epilepsy.

About Nile
Nile is an independent company that seeks to improve care for people living=
with epilepsy, their caregivers and healthcare providers. Nile is on a mis=
sion to make the journey of every epilepsy patient predictable. Its digital=
epilepsy care management platform will provide tools for people living wit=
h epilepsy and providers to progress to data-driven, personalized care. Nil=
e is a collaboration-driven organization and is welcoming partners in this =
mission. For more information, visit www.Nile.ai and email info@Nile.ai.

For further information, UCB:

UCB Communications
Erica Puntel
Digital Business Transformation, UCB
T 404.938.5359, erica.puntel@ucb.com =C2=A0=C2=A0

Laurent Schots
Global Communications, UCB
T: +32 (0)2 559 92 64, laurent.schots@ucb.com

Investor Relations
Antje Witte
Investor Relations, UCB =C2=A0=C2=A0
T +32.2.559.94.14, antje.witte@ucb.com =C2=A0=C2=A0

Isabelle Ghellynck
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com

For further information, Nile:

Nile AI, Inc.
T 818.351.9744, info@Nile.ai


Forward looking statements =E2=80=93 UCB
This press release contains forward-looking statements based on current pla=
ns, estimates and beliefs of management. All statements, other than stateme=
nts of historical fact, are statements that could be deemed forward-looking=
statements, including estimates of revenues, operating margins, capital ex=
penditures, cash, other financial information, expected legal, political, r=
egulatory or clinical results and other such estimates and results. By thei=
r nature, such forward-looking statements are not guarantees of future perf=
ormance and are subject to risks, uncertainties and assumptions which could=
cause actual results to differ materially from those that may be implied b=
y such forward-looking statements contained in this press release. Importan=
t factors that could result in such differences include: changes in general=
economic, business and competitive conditions, the inability to obtain nec=
essary regulatory approvals or to obtain them on acceptable terms, costs as=
sociated with research and development, changes in the prospects for produc=
ts in the pipeline or under development by UCB, effects of future judicial =
decisions or governmental investigations, product liability claims, challen=
ges to patent protection for products or product candidates, changes in law=
s or regulations, exchange rate fluctuations, changes or uncertainties in t=
ax laws or the administration of such laws and hiring and retention of its =

UCB is providing this information as of the date of this press release and =
expressly disclaims any duty to update any information contained in this pr=
ess release, either to confirm the actual results or to report a change in =
its expectations. There is no guarantee that new product candidates in the =
pipeline will progress to product approval or that new indications for exis=
ting products will be developed and approved. Products or potential product=
s which are the subject of partnerships, joint ventures or licensing collab=
orations may be subject to differences between the partners. Also, UCB or o=
thers could discover safety, side effects or manufacturing problems with it=
s products after they are marketed. Moreover, sales may be impacted by inte=
rnational and domestic trends toward managed care and health care cost cont=
ainment and the reimbursement policies imposed by third-party payers as wel=
l as legislation affecting biopharmaceutical pricing and reimbursement.
UCB - Nile - Press Release - FINAL (https://mb.cision.com/Public/18595/3267=
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x58118x1x6868579x24000=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=